MGTX
MeiraGTx Holdings PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$774.55M
P/E Ratio
—
EPS
$-1.42
Beta
1.28
52W High
$9.88
52W Low
$4.55
50-Day MA
$7.71
200-Day MA
$7.91
Dividend Yield
—
Profit Margin
-140.30%
Forward P/E
1.61
PEG Ratio
—
About MeiraGTx Holdings PLC
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $81.39M |
| Gross Profit (TTM) | $76.55M |
| EBITDA | $-93.43M |
| Operating Margin | 35.10% |
| Return on Equity | -368.20% |
| Return on Assets | -25.80% |
| Revenue/Share (TTM) | $1.01 |
| Book Value | $-0.07 |
| Price-to-Book | 225.31 |
| Price-to-Sales (TTM) | 9.52 |
| EV/Revenue | 9.47 |
| EV/EBITDA | -3.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 252.30% |
| Shares Outstanding | $81.45M |
| Float | $42.31M |
| % Insiders | 19.97% |
| % Institutions | 65.56% |
Analyst Ratings
Consensus ($26.00 target)
2
Strong Buy6
BuyData last updated: 4/8/2026